markedly significantp < 0.001
Furthermore, patients with abnormal levels of ≤2 metals showed a markedly significant ( p < 0.001) difference in overall survival outcomes compared to patients with abnormal levels of >3 metals (median survival: 41.72 vs. 19.13 months; Figure 4B ).